Syndax Pharmaceuticals (SNDX) investor relations material

Commercial and product performance

• Two leading oncology products launched: Revuforj for acute leukemia and Niktimvo for chronic GVHD, both showing strong sales growth and market uptake.

• Revuforj is now standard of care for KMT2A and NPM1 acute leukemia, with increasing use in earlier treatment lines and maintenance therapy, expected to extend average duration of therapy from 4–6 months in 2025 to 6–12 months in 2026.

• Niktimvo achieved $152 million in sales within its first year, with expanding use in third-line chronic GVHD and ongoing pivotal and phase II trials in combination settings.

Competitive positioning and physician adoption

• Revuforj holds the broadest label and best efficacy among menin inhibitors, covering adults and pediatrics in AML and ALL, with strong physician support and rapid drug access.

• Combination and real-world data are being leveraged to maintain leadership and drive further uptake, with significant new data expected in 2026.

Financial strategy and capital allocation

• Operating expenses are kept flat at $400 million for SG&A and R&D, supported by high gross margins from two successful product launches.

• Focus remains on maintaining leadership in menin inhibition, co-promoting Niktimvo, and advancing both products to frontline and combination settings.